 |
PDBsum entry 2if5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
2if5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Structure of the poz domain of human lrf, A master regulator of oncogenesis.
|
|
|
Authors
|
|
F.D.Schubot,
J.E.Tropea,
D.S.Waugh.
|
|
|
Ref.
|
|
Biochem Biophys Res Commun, 2006,
351,
1-6.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
The proto-oncogenic properties of the POK family of transcriptional repressors
BCL6, PLZF, and LRF have been well established. These proteins utilize their
amino-terminal POZ domains for multimerization and the recruitment of
co-repressors. Because LRF represses the production of the tumor suppressor
p19(Arf) (ARF), it is regarded as an attractive therapeutic target for the
treatment of many types of cancer. The crystal structure of the LRF POZ domain
reveals a high degree of structural conservation with the corresponding domains
of BCL6 and PLZF. However, striking differences between the electrostatic
properties of the BCL6 and LRF POZ domains suggest that if, like BCL6, LRF
interacts with the co-repressor SMRT, it almost certainly uses a different
mechanism to do so. These differences may also explain why LRF interacts with
BCL6 but not with PLZF. Finally, the conservation of crystal packing contacts
suggests the probable location of the interface that mediates LRF/BCL6 complex
formation.
|
|
|
|
|
|
|
